Gladstone Institutional Advisory LLC
Position in GALT — Galectin Therapeutics Inc
CIK 1766530
Bedminster, NJ
Position in GALT
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$110,896
+$44,215 QoQ
Shares Held
23,900
0.0% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#48
of 98 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GALT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gladstone Institutional Advisory LLC holds $1,952,269 across 9 Biotechnology names. GALT ranks #5 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GPCR |
Structure Therapeutics Inc.
|
13,275 | $712,469 | |
| 2 | IBRX |
ImmunityBio, Inc.
|
50,818 | $444,911 | |
| 3 | VKTX |
Viking Therapeutics, Inc.
|
9,527 | $371,648 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
383 | $238,815 | |
| 5 | GALT |
Galectin Therapeutics Inc
This page
|
23,900 | $110,896 | |
| 6 | AVXL |
Anavex Life Sciences Corp.
|
17,671 | $45,767 | |
| 7 | CRDF |
Cardiff Oncology, Inc.
|
13,000 | $16,900 | |
| 8 | ATYR |
aTYR PHARMA INC
|
11,300 | $6,746 |
All Filings in GALT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $110,896 | 23,900 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $66,681 | 23,900 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $99,424 | 23,900 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $104,516 | 24,650 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $52,011 | 24,650 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $30,073 | 24,650 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $31,798 | 24,650 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $59,812 | 21,750 | Shares | Sole | 2024-10-28 | |
| No filing history on record for this holder in this stock. | ||||||